Web Desc
Drug Discovery for Protozoan Parasites
Organizer(s): Dennis E. Kyle, Michael A.J. Ferguson and Susan Charman
Date: March 22 - 26, 2009
Location: Beaver Run Resort, Breckenridge, CO, USA
Part of the Keystone Symposia Global Health Series, Supported by the Bill & Melinda Gates Foundation
For important information on the coronavirus, please click here
Summary of Meeting:
The discovery and development of new drugs for protozoan parasites has rapidly expanded to include multidisciplinary approaches from academia, government, and industry. Public-private partnerships have focused efforts on translational research and as a result, new drugs have been advanced into clinical evaluation. Unfortunately, development of several promising new drugs has recently been terminated in clinical trials thus leaving a sparse pipeline of new chemical entities that have potential for registration in the next few years. Importantly, the need for effective new drugs for major human parasitic diseases (malaria, leishmaniasis, and trypanosomiasis) is growing and concerns over antimalarial resistance to artemisinin-based drugs are building. This meeting will bring together chemists, biologists, pharmacologists, and clinicians to find solutions to accelerate drug discovery efforts. Key problems to be addressed include identification and validation of new targets, chemical biology and medicinal chemistry approaches to characterize new compounds, novel screening techniques to identify new chemotypes, mechanisms of drug resistance, and cutting edge strategies to progress new drug candidates into clinical trials. The objectives of this meeting are to discuss current methods to identify and validate new drug targets and to screen libraries of compounds to discover novel chemotypes; assess the potential for chemical biology and medicinal chemistry to optimize compounds that are specific and avoid resistance mechanisms; and identify critical paths for compound progression and to discuss the utility of key models for assessing preclinical drug leads.
Global Health Travel Award Deadline: October 6 2008
Scholarship Deadline: November 24 2008
Discounted Abstract Deadline: November 24 2008
Abstract Deadline: December 22 2008
Discounted Registration Deadline: January 22 2009
We gratefully acknowledge additional support for this conference from:
Bill & Melinda Gates FoundationScynexis, Inc.
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:
Cell Press
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:

Click here to view more of these organizations

Program

Sunday, March 22 | 3:00PM - 7:30PM
Registration
Room: Foyer


Sunday, March 22 | 6:30PM - 7:30PM
Refreshments
Room: Foyer


Sunday, March 22 | 7:30PM - 8:30PM
Keynote Address
Room: Peak 5

Speaker 1 of 1
William N. Charman, Monash University, Australia
Drug Discovery for Protozoan Parasites – The Essential P’s

Monday, March 23 | 7:00AM - 8:00AM
Breakfast
Room: Peaks 1-4


Monday, March 23 | 8:00AM - 11:15AM
Target Identification and Validation
Room: Peak 5

Speaker 1 of 6
* Dennis E. Kyle, University of Georgia, USA

Monday, March 23 | 8:00AM - 11:15AM
Target Identification and Validation
Room: Peak 5

Speaker 2 of 6
John H. Adams, University of South Florida College of Public Health, COPH, USA
Validation of Blood Stage Targets for Malaria Drug Discovery

Monday, March 23 | 8:00AM - 11:15AM
Target Identification and Validation
Room: Peak 5

Speaker 3 of 6
Lizbeth Hedstrom, Brandeis University, USA
Targeting a Prokaryotic Protein in Eukaryotic Parasite

Monday, March 23 | 8:00AM - 11:15AM
Target Identification and Validation
Room: Peak 5

Speaker 4 of 6
Michael A.J. Ferguson, University of Dundee, UK
Glycoprotein Biosynthesis in Trypanosoma brucei: Host/Parasite Differences and Therapeutic Potential

Monday, March 23 | 8:00AM - 11:15AM
Target Identification and Validation
Room: Peak 5

Speaker 5 of 6
Andrew Hopkins, University of Dundee, UK
An Informatics-Based Approach to Target Identification

Monday, March 23 | 8:00AM - 11:15AM
Target Identification and Validation
Room: Peak 5

Speaker 6 of 6
Meg Phillips, University of Texas Southwestern Medical Center, USA
Short Talk: Structure Function Analysis of Species Specificity in Malarial Dihydroorotate Dehydrogenases

Monday, March 23 | 9:20AM - 9:40AM
Coffee Break
Room: Foyer


Monday, March 23 | 11:15AM - 11:15AM
On Own for Lunch


Monday, March 23 | 11:15AM - 1:00PM
Poster Setup
Room: Peaks 1-4


Monday, March 23 | 11:15AM - 11:30AM
Q & A Session
Room: Peak 5

Speaker 1 of 1
Martin John Rogers, NIAID, National Institutes of Health, USA
Update on the New NIH Stimulus Grants

Monday, March 23 | 1:00PM - 10:00PM
Poster Viewing
Room: Peaks 1-4


Monday, March 23 | 2:30PM - 4:30PM
Workshop 1: Target Validation: Myths and Reality
Room: Peak 5

Speaker 1 of 6
* Michael A.J. Ferguson, University of Dundee, UK

Monday, March 23 | 2:30PM - 4:30PM
Workshop 1: Target Validation: Myths and Reality
Room: Peak 5

Speaker 2 of 6
Jeremy N. Burrows, Medicines for Malaria Venture, Switzerland

Monday, March 23 | 2:30PM - 4:30PM
Workshop 1: Target Validation: Myths and Reality
Room: Peak 5

Speaker 3 of 6
Michael A.J. Ferguson, University of Dundee, UK

Monday, March 23 | 2:30PM - 4:30PM
Workshop 1: Target Validation: Myths and Reality
Room: Peak 5

Speaker 4 of 6
James Morris, Clemson University, USA

Monday, March 23 | 2:30PM - 4:30PM
Workshop 1: Target Validation: Myths and Reality
Room: Peak 5

Speaker 5 of 6
John H. Adams, University of South Florida College of Public Health, COPH, USA

Monday, March 23 | 2:30PM - 4:30PM
Workshop 1: Target Validation: Myths and Reality
Room: Peak 5

Speaker 6 of 6
Babu Tekwani, University of Mississippi School of Pharmacy, USA

Monday, March 23 | 4:30PM - 5:00PM
Coffee Available
Room: Foyer


Monday, March 23 | 5:00PM - 7:00PM
Chemical Biology
Room: Peak 5

Speaker 1 of 5
* Michael A.J. Ferguson, University of Dundee, UK

Monday, March 23 | 5:00PM - 7:00PM
Chemical Biology
Room: Peak 5

Speaker 2 of 5
Leann M. Tilley, University of Melbourne, Australia
The Digestive Vacuole as an Antimalarial Drug Target

Monday, March 23 | 5:00PM - 7:00PM
Chemical Biology
Room: Peak 5

Speaker 3 of 5
Pradipsinh K. Rathod, University of Washington, USA
Novel Mechanisms Underlying Antifolate Drug Selectivity

Monday, March 23 | 5:00PM - 7:00PM
Chemical Biology
Room: Peak 5

Speaker 4 of 5
Timothy A.J. Haystead, Duke University, USA
Chemoproteomics of the Malaria Purinome

Monday, March 23 | 5:00PM - 7:00PM
Chemical Biology
Room: Peak 5

Speaker 5 of 5
Amy K. Wernimont, National Institutes of Health, USA
Short Talk: Structural Analyses and Chemical Biology – Targeting the Kinome of Apicomplexan Parasites

Monday, March 23 | 7:00PM - 8:00PM
Social Hour with Lite Bites
Room: Peaks 1-4


Monday, March 23 | 7:30PM - 10:00PM
Poster Session 1
Room: Peaks 1-4


Tuesday, March 24 | 7:00AM - 8:00AM
Breakfast
Room: Peaks 1-4


Tuesday, March 24 | 8:00AM - 11:15AM
Compounds
Room: Peak 5

Speaker 1 of 7
* Susan A. Charman, Monash University, Australia

Tuesday, March 24 | 8:00AM - 11:15AM
Compounds
Room: Peak 5

Speaker 2 of 7
Dominique Mazier, Université Pierre et Marie Curie, France
Novel Approaches for the Identification of Molecules Active on the Hepatic Stages of Malaria

Tuesday, March 24 | 8:00AM - 11:15AM
Compounds
Room: Peak 5

Speaker 3 of 7
Karl A. Werbovetz, Ohio State University, USA
Arylimidamides as New Antileishmanial Drug Candidates

Tuesday, March 24 | 8:00AM - 11:15AM
Compounds
Room: Peak 5

Speaker 4 of 7
Paul M. O'Neill, University of Liverpool, UK
Novel Strategies for Antimalarial Chemotherapy and Candidate Selection of a Novel 1,2,4,5-Tetraoxane with Antimalarial Properties Superior to the Semi-Synthetic Artemisinins

Tuesday, March 24 | 8:00AM - 11:15AM
Compounds
Room: Peak 5

Speaker 5 of 7
Robert Don, Drugs for Neglected Diseases Initiative, Switzerland
The Drugs for Neglected Diseases Initiative – A Product Development Partnership Developing New Drugs for Neglected Tropical Infectious Diseases

Tuesday, March 24 | 8:00AM - 11:15AM
Compounds
Room: Peak 5

Speaker 6 of 7
Robert H. Barker, Sanofi Genzyme, USA
Short Talk: A Medicinal Chemistry Program for the Discovery of Plasmodium falciparum Dihydroorotate Dehydrogenase Inhibitors with Antimalarial Activity

Tuesday, March 24 | 8:00AM - 11:15AM
Compounds
Room: Peak 5

Speaker 7 of 7
Michael H. Gelb, University of Washington, USA
Short Talk: Lanosterol 14alpha-Demethylase Inhibitors as Anti-Chagas Disease Drug Candidates

Tuesday, March 24 | 9:20AM - 9:40AM
Coffee Break
Room: Foyer


Tuesday, March 24 | 11:15AM - 11:15AM
On Own for Lunch


Tuesday, March 24 | 11:15AM - 1:00PM
Poster Setup
Room: Peaks 1-4


Tuesday, March 24 | 1:00PM - 10:00PM
Poster Viewing
Room: Peaks 1-4


Tuesday, March 24 | 4:30PM - 5:00PM
Coffee Available
Room: Foyer


Tuesday, March 24 | 5:00PM - 7:00PM
Screening
Room: Peak 5

Speaker 1 of 5
* Karl A. Werbovetz, Ohio State University, USA

Tuesday, March 24 | 5:00PM - 7:00PM
Screening
Room: Peak 5

Speaker 2 of 5
John S. Lazo, University of Pittsburgh, USA
High Throughput and High Content Screens for Agents Targeting Neglected Diseases

Tuesday, March 24 | 5:00PM - 7:00PM
Screening
Room: Peak 5

Speaker 3 of 5
Ronald J. Quinn, Griffith University, Australia
High Throughput Screening of Natural Products

Tuesday, March 24 | 5:00PM - 7:00PM
Screening
Room: Peak 5

Speaker 4 of 5
Julie Ann Frearson, University of Dundee, UK
Hit Discovery for HAT; Molecular Target versus Phenotypic Strategies

Tuesday, March 24 | 5:00PM - 7:00PM
Screening
Room: Peak 5

Speaker 5 of 5
Rafaela Salgado Ferreira, São Carlos Physics Institute, Brazil
Short Talk: Successes and Failures in using Virtual Screening to Predict the Results of a High Throughput Screen Against Cruzain

Tuesday, March 24 | 7:00PM - 8:00PM
Social Hour with Lite Bites
Room: Peaks 1-4


Tuesday, March 24 | 7:30PM - 10:00PM
Poster Session 2
Room: Peaks 1-4


Wednesday, March 25 | 7:00AM - 8:00AM
Breakfast
Room: Peaks 1-4


Wednesday, March 25 | 8:00AM - 11:15AM
Drug Resistance
Room: Peak 5

Speaker 1 of 6
* Pradipsinh K. Rathod, University of Washington, USA

Wednesday, March 25 | 8:00AM - 11:15AM
Drug Resistance
Room: Peak 5

Speaker 2 of 6
Rentala Madhubala, Jawaharlal Nehru University, India
Identification of Potential Biomarkers for Antimony Susceptibility / Resistance in L. donovani

Wednesday, March 25 | 8:00AM - 11:15AM
Drug Resistance
Room: Peak 5

Speaker 3 of 6
Ric N. Price, Menzies School of Health Research, Australia
Drug Resistance in Vivax Malaria

Wednesday, March 25 | 8:00AM - 11:15AM
Drug Resistance
Room: Peak 5

Speaker 4 of 6
Arjen M. Dondorp, Wellcome Trust-Mahidol University, Thailand
Susceptibility to Artesunate of Plasmodium falciparum in Southeast Asia

Wednesday, March 25 | 8:00AM - 11:15AM
Drug Resistance
Room: Peak 5

Speaker 5 of 6
Dennis E. Kyle, University of Georgia, USA
Discovery of Antimalarial Drug Combinations to Combat Drug Resistance

Wednesday, March 25 | 8:00AM - 11:15AM
Drug Resistance
Room: Peak 5

Speaker 6 of 6
Maria Gonzalez-Pons, University of Puerto Rico School of Medicine, USA
Short Talk: Disruption of the Multidrug Resistance Associated Protein (pbmrp) Gene in Plasmodium berghei

Wednesday, March 25 | 9:20AM - 9:40AM
Coffee Break
Room: Foyer


Wednesday, March 25 | 11:15AM - 11:15AM
On Own for Lunch


Wednesday, March 25 | 2:30PM - 4:30PM
Workshop 2: Drug Discovery in Academia
Room: Peak 5

Speaker 1 of 7
* Susan A. Charman, Monash University, Australia

Wednesday, March 25 | 2:30PM - 4:30PM
Workshop 2: Drug Discovery in Academia
Room: Peak 5

Speaker 2 of 7
Ian C. Bathurst, Medicines for Malaria Ventures, Switzerland

Wednesday, March 25 | 2:30PM - 4:30PM
Workshop 2: Drug Discovery in Academia
Room: Peak 5

Speaker 3 of 7
Robert Don, Drugs for Neglected Diseases Initiative, Switzerland

Wednesday, March 25 | 2:30PM - 4:30PM
Workshop 2: Drug Discovery in Academia
Room: Peak 5

Speaker 4 of 7
Ken Duncan, Bill & Melinda Gates Foundation, USA

Wednesday, March 25 | 2:30PM - 4:30PM
Workshop 2: Drug Discovery in Academia
Room: Peak 5

Speaker 5 of 7
S A. Ward, University of Liverpool, UK

Wednesday, March 25 | 2:30PM - 4:30PM
Workshop 2: Drug Discovery in Academia
Room: Peak 5

Speaker 6 of 7
R. Kip Guy, St. Jude Children's Research Hospital, USA

Wednesday, March 25 | 2:30PM - 4:30PM
Workshop 2: Drug Discovery in Academia
Room: Peak 5

Speaker 7 of 7
William N. Charman, Monash University, Australia

Wednesday, March 25 | 4:30PM - 5:00PM
Coffee Available
Room: Foyer


Wednesday, March 25 | 5:00PM - 7:00PM
Preclinical Progression
Room: Peak 5

Speaker 1 of 5
* Michael H. Gelb, University of Washington, USA

Wednesday, March 25 | 5:00PM - 7:00PM
Preclinical Progression
Room: Peak 5

Speaker 2 of 5
R. Kip Guy, St. Jude Children's Research Hospital, USA
Early Lead Optimization for a Novel Series of Antimalarials

Wednesday, March 25 | 5:00PM - 7:00PM
Preclinical Progression
Room: Peak 5

Speaker 3 of 5
Susan A. Charman, Monash University, Australia
ADME Lead Optimization: Application to a Novel Antimalarial Drug Discovery Program

Wednesday, March 25 | 5:00PM - 7:00PM
Preclinical Progression
Room: Peak 5

Speaker 4 of 5
Reto Brun, Swiss Tropical Institute, Switzerland
Pros and Cons of Rodent Models for Malaria and HAT

Wednesday, March 25 | 5:00PM - 7:00PM
Preclinical Progression
Room: Peak 5

Speaker 5 of 5
Robert T. Jacobs, Anacor Pharmaceuticals, Inc., USA
Short Talk: Novel Oxaborole 6-Carboxamides Demonstrate Potential for Treatment of CNS-Stage Human African Trypanosomiasis

Wednesday, March 25 | 7:00PM - 8:00PM
Social Hour with Lite Bites
Room: Peaks 1-4


Wednesday, March 25 | 8:00PM - 11:00PM
Entertainment
Room: Peaks 1-4


Wednesday, March 25 | 8:00PM - 11:00PM
Cash Bar
Room: Peaks 1-4


Thursday, March 26 | 10:22AM - 10:22AM
Departure


*Session Chair
†Invited, not yet responded.